Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma
To evaluate the antitumor response, time-to-event efficacy endpoints and toxicity of plitidepsin (Aplidin) 5 mg/m as a 3-hour intravenous (i.v.) infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma (MTC). Sixteen patients with MTC and disease progression or large...
Gespeichert in:
Veröffentlicht in: | American journal of clinical oncology 2010-02, Vol.33 (1), p.83-88 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 88 |
---|---|
container_issue | 1 |
container_start_page | 83 |
container_title | American journal of clinical oncology |
container_volume | 33 |
creator | Baudin, Eric Droz, Jean P Paz-Ares, Luis van Oosterom, Allan T Cullell-Young, Martin Schlumberger, Martin |
description | To evaluate the antitumor response, time-to-event efficacy endpoints and toxicity of plitidepsin (Aplidin) 5 mg/m as a 3-hour intravenous (i.v.) infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma (MTC).
Sixteen patients with MTC and disease progression or large tumor burden received plitidepsin. Tumor response and time-related parameters were evaluated according to Response Evaluation Criteria in Solid Tumors. Secondary efficacy endpoints were marker response (calcitonin and carcinoembryonic antigen), clinical benefit and quality of life. Safety was assessed using the National Cancer Institute Common Toxicity Criteria.
A total of 141 cycles (median, 9 per patient; range, 1-24) were administered. No complete responses or partial responses (PR) were found, and 12 patients had stable disease for >8 weeks. Median follow-up was 15.0 months. Median time to progression was 5.3 months. Median overall survival could not be calculated, but 86.7% and 66.0% of patients were alive at 6 and 12 months. Marker response included 1 unconfirmed PR and 2 stabilizations for calcitonin, and 1 unconfirmed PR and 4 stabilizations for calcitonin and carcinoembryonic antigen. One patient showed clinical benefit. Quality of life scores generally decreased during the study. Most treatment-related adverse events were mild or moderate. Grade 3 lymphopenia was the only severe hematological toxicity found (2 patients). Severe nonhematological toxicities were grade 3 creatine phosphokinase increase (2 patients, with no myalgia or muscular weakness) and transient grade 3 alanine aminotransferase increase (5 patients).
Single-agent plitidepsin given as 3-hour i.v. infusions every 2 weeks was generally well tolerated but showed limited clinical activity in patients with unresectable advanced MTC. |
doi_str_mv | 10.1097/COC.0b013e31819fdf5e |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_COC_0b013e31819fdf5e</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19704366</sourcerecordid><originalsourceid>FETCH-LOGICAL-c306t-bd35bca1ef8c3f60464a04a2de6af49388952278675ab78c28fdab82e04adff93</originalsourceid><addsrcrecordid>eNpdkF1LwzAUhoMobk7_gUj-QGc-2qS9lOLHYDAvFLwraXJCo11bknRjN_52KxsIXh04nOfwvg9Ct5QsKSnkfbkpl6QmlAOnOS2ssRmcoTnNuEzSjH-cozlhUiZccjZDVyF8EkIyQeQlmtFCkpQLMUffr40KgFcrHOJoDri3eGhddAaG4DrMk6YfPXadHYPrOww78AfM8B7gK0xrPKjooIsB711s8Nh5CKCjqlvAyuxUp8HgLZixbdUExubge2ewVl67rt-qa3RhVRvg5jQX6P3p8a18Sdab51X5sE40JyImteFZrRUFm2tuBUlFqkiqmAGhbFrwPC8yxmQuZKZqmWuWW6PqnMF0ZKwt-AKlx7_a9yF4sNXg3XaKVFFS_eqsJp3Vf50TdnfEhrGeWvxBJ3_8BxIDdbY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma</title><source>MEDLINE</source><source>Journals@Ovid Ovid Autoload</source><creator>Baudin, Eric ; Droz, Jean P ; Paz-Ares, Luis ; van Oosterom, Allan T ; Cullell-Young, Martin ; Schlumberger, Martin</creator><creatorcontrib>Baudin, Eric ; Droz, Jean P ; Paz-Ares, Luis ; van Oosterom, Allan T ; Cullell-Young, Martin ; Schlumberger, Martin</creatorcontrib><description>To evaluate the antitumor response, time-to-event efficacy endpoints and toxicity of plitidepsin (Aplidin) 5 mg/m as a 3-hour intravenous (i.v.) infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma (MTC).
Sixteen patients with MTC and disease progression or large tumor burden received plitidepsin. Tumor response and time-related parameters were evaluated according to Response Evaluation Criteria in Solid Tumors. Secondary efficacy endpoints were marker response (calcitonin and carcinoembryonic antigen), clinical benefit and quality of life. Safety was assessed using the National Cancer Institute Common Toxicity Criteria.
A total of 141 cycles (median, 9 per patient; range, 1-24) were administered. No complete responses or partial responses (PR) were found, and 12 patients had stable disease for >8 weeks. Median follow-up was 15.0 months. Median time to progression was 5.3 months. Median overall survival could not be calculated, but 86.7% and 66.0% of patients were alive at 6 and 12 months. Marker response included 1 unconfirmed PR and 2 stabilizations for calcitonin, and 1 unconfirmed PR and 4 stabilizations for calcitonin and carcinoembryonic antigen. One patient showed clinical benefit. Quality of life scores generally decreased during the study. Most treatment-related adverse events were mild or moderate. Grade 3 lymphopenia was the only severe hematological toxicity found (2 patients). Severe nonhematological toxicities were grade 3 creatine phosphokinase increase (2 patients, with no myalgia or muscular weakness) and transient grade 3 alanine aminotransferase increase (5 patients).
Single-agent plitidepsin given as 3-hour i.v. infusions every 2 weeks was generally well tolerated but showed limited clinical activity in patients with unresectable advanced MTC.</description><identifier>ISSN: 0277-3732</identifier><identifier>EISSN: 1537-453X</identifier><identifier>DOI: 10.1097/COC.0b013e31819fdf5e</identifier><identifier>PMID: 19704366</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Aged ; Brain Stem Neoplasms - drug therapy ; Brain Stem Neoplasms - secondary ; Depsipeptides - administration & dosage ; Female ; Humans ; Infusions, Intravenous ; Lymphatic Metastasis ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis ; Survival Rate ; Thyroid Neoplasms - drug therapy ; Thyroid Neoplasms - pathology ; Treatment Outcome</subject><ispartof>American journal of clinical oncology, 2010-02, Vol.33 (1), p.83-88</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c306t-bd35bca1ef8c3f60464a04a2de6af49388952278675ab78c28fdab82e04adff93</citedby><cites>FETCH-LOGICAL-c306t-bd35bca1ef8c3f60464a04a2de6af49388952278675ab78c28fdab82e04adff93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19704366$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Baudin, Eric</creatorcontrib><creatorcontrib>Droz, Jean P</creatorcontrib><creatorcontrib>Paz-Ares, Luis</creatorcontrib><creatorcontrib>van Oosterom, Allan T</creatorcontrib><creatorcontrib>Cullell-Young, Martin</creatorcontrib><creatorcontrib>Schlumberger, Martin</creatorcontrib><title>Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma</title><title>American journal of clinical oncology</title><addtitle>Am J Clin Oncol</addtitle><description>To evaluate the antitumor response, time-to-event efficacy endpoints and toxicity of plitidepsin (Aplidin) 5 mg/m as a 3-hour intravenous (i.v.) infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma (MTC).
Sixteen patients with MTC and disease progression or large tumor burden received plitidepsin. Tumor response and time-related parameters were evaluated according to Response Evaluation Criteria in Solid Tumors. Secondary efficacy endpoints were marker response (calcitonin and carcinoembryonic antigen), clinical benefit and quality of life. Safety was assessed using the National Cancer Institute Common Toxicity Criteria.
A total of 141 cycles (median, 9 per patient; range, 1-24) were administered. No complete responses or partial responses (PR) were found, and 12 patients had stable disease for >8 weeks. Median follow-up was 15.0 months. Median time to progression was 5.3 months. Median overall survival could not be calculated, but 86.7% and 66.0% of patients were alive at 6 and 12 months. Marker response included 1 unconfirmed PR and 2 stabilizations for calcitonin, and 1 unconfirmed PR and 4 stabilizations for calcitonin and carcinoembryonic antigen. One patient showed clinical benefit. Quality of life scores generally decreased during the study. Most treatment-related adverse events were mild or moderate. Grade 3 lymphopenia was the only severe hematological toxicity found (2 patients). Severe nonhematological toxicities were grade 3 creatine phosphokinase increase (2 patients, with no myalgia or muscular weakness) and transient grade 3 alanine aminotransferase increase (5 patients).
Single-agent plitidepsin given as 3-hour i.v. infusions every 2 weeks was generally well tolerated but showed limited clinical activity in patients with unresectable advanced MTC.</description><subject>Adult</subject><subject>Aged</subject><subject>Brain Stem Neoplasms - drug therapy</subject><subject>Brain Stem Neoplasms - secondary</subject><subject>Depsipeptides - administration & dosage</subject><subject>Female</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Lymphatic Metastasis</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>Survival Rate</subject><subject>Thyroid Neoplasms - drug therapy</subject><subject>Thyroid Neoplasms - pathology</subject><subject>Treatment Outcome</subject><issn>0277-3732</issn><issn>1537-453X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkF1LwzAUhoMobk7_gUj-QGc-2qS9lOLHYDAvFLwraXJCo11bknRjN_52KxsIXh04nOfwvg9Ct5QsKSnkfbkpl6QmlAOnOS2ssRmcoTnNuEzSjH-cozlhUiZccjZDVyF8EkIyQeQlmtFCkpQLMUffr40KgFcrHOJoDri3eGhddAaG4DrMk6YfPXadHYPrOww78AfM8B7gK0xrPKjooIsB711s8Nh5CKCjqlvAyuxUp8HgLZixbdUExubge2ewVl67rt-qa3RhVRvg5jQX6P3p8a18Sdab51X5sE40JyImteFZrRUFm2tuBUlFqkiqmAGhbFrwPC8yxmQuZKZqmWuWW6PqnMF0ZKwt-AKlx7_a9yF4sNXg3XaKVFFS_eqsJp3Vf50TdnfEhrGeWvxBJ3_8BxIDdbY</recordid><startdate>201002</startdate><enddate>201002</enddate><creator>Baudin, Eric</creator><creator>Droz, Jean P</creator><creator>Paz-Ares, Luis</creator><creator>van Oosterom, Allan T</creator><creator>Cullell-Young, Martin</creator><creator>Schlumberger, Martin</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201002</creationdate><title>Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma</title><author>Baudin, Eric ; Droz, Jean P ; Paz-Ares, Luis ; van Oosterom, Allan T ; Cullell-Young, Martin ; Schlumberger, Martin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c306t-bd35bca1ef8c3f60464a04a2de6af49388952278675ab78c28fdab82e04adff93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Brain Stem Neoplasms - drug therapy</topic><topic>Brain Stem Neoplasms - secondary</topic><topic>Depsipeptides - administration & dosage</topic><topic>Female</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Lymphatic Metastasis</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>Survival Rate</topic><topic>Thyroid Neoplasms - drug therapy</topic><topic>Thyroid Neoplasms - pathology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baudin, Eric</creatorcontrib><creatorcontrib>Droz, Jean P</creatorcontrib><creatorcontrib>Paz-Ares, Luis</creatorcontrib><creatorcontrib>van Oosterom, Allan T</creatorcontrib><creatorcontrib>Cullell-Young, Martin</creatorcontrib><creatorcontrib>Schlumberger, Martin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>American journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baudin, Eric</au><au>Droz, Jean P</au><au>Paz-Ares, Luis</au><au>van Oosterom, Allan T</au><au>Cullell-Young, Martin</au><au>Schlumberger, Martin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma</atitle><jtitle>American journal of clinical oncology</jtitle><addtitle>Am J Clin Oncol</addtitle><date>2010-02</date><risdate>2010</risdate><volume>33</volume><issue>1</issue><spage>83</spage><epage>88</epage><pages>83-88</pages><issn>0277-3732</issn><eissn>1537-453X</eissn><abstract>To evaluate the antitumor response, time-to-event efficacy endpoints and toxicity of plitidepsin (Aplidin) 5 mg/m as a 3-hour intravenous (i.v.) infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma (MTC).
Sixteen patients with MTC and disease progression or large tumor burden received plitidepsin. Tumor response and time-related parameters were evaluated according to Response Evaluation Criteria in Solid Tumors. Secondary efficacy endpoints were marker response (calcitonin and carcinoembryonic antigen), clinical benefit and quality of life. Safety was assessed using the National Cancer Institute Common Toxicity Criteria.
A total of 141 cycles (median, 9 per patient; range, 1-24) were administered. No complete responses or partial responses (PR) were found, and 12 patients had stable disease for >8 weeks. Median follow-up was 15.0 months. Median time to progression was 5.3 months. Median overall survival could not be calculated, but 86.7% and 66.0% of patients were alive at 6 and 12 months. Marker response included 1 unconfirmed PR and 2 stabilizations for calcitonin, and 1 unconfirmed PR and 4 stabilizations for calcitonin and carcinoembryonic antigen. One patient showed clinical benefit. Quality of life scores generally decreased during the study. Most treatment-related adverse events were mild or moderate. Grade 3 lymphopenia was the only severe hematological toxicity found (2 patients). Severe nonhematological toxicities were grade 3 creatine phosphokinase increase (2 patients, with no myalgia or muscular weakness) and transient grade 3 alanine aminotransferase increase (5 patients).
Single-agent plitidepsin given as 3-hour i.v. infusions every 2 weeks was generally well tolerated but showed limited clinical activity in patients with unresectable advanced MTC.</abstract><cop>United States</cop><pmid>19704366</pmid><doi>10.1097/COC.0b013e31819fdf5e</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0277-3732 |
ispartof | American journal of clinical oncology, 2010-02, Vol.33 (1), p.83-88 |
issn | 0277-3732 1537-453X |
language | eng |
recordid | cdi_crossref_primary_10_1097_COC_0b013e31819fdf5e |
source | MEDLINE; Journals@Ovid Ovid Autoload |
subjects | Adult Aged Brain Stem Neoplasms - drug therapy Brain Stem Neoplasms - secondary Depsipeptides - administration & dosage Female Humans Infusions, Intravenous Lymphatic Metastasis Male Middle Aged Neoplasm Staging Prognosis Survival Rate Thyroid Neoplasms - drug therapy Thyroid Neoplasms - pathology Treatment Outcome |
title | Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T22%3A55%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20II%20study%20of%20plitidepsin%203-hour%20infusion%20every%202%20weeks%20in%20patients%20with%20unresectable%20advanced%20medullary%20thyroid%20carcinoma&rft.jtitle=American%20journal%20of%20clinical%20oncology&rft.au=Baudin,%20Eric&rft.date=2010-02&rft.volume=33&rft.issue=1&rft.spage=83&rft.epage=88&rft.pages=83-88&rft.issn=0277-3732&rft.eissn=1537-453X&rft_id=info:doi/10.1097/COC.0b013e31819fdf5e&rft_dat=%3Cpubmed_cross%3E19704366%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/19704366&rfr_iscdi=true |